Skip to Content

Biological Sciences Profiles


Wen Chen

Professor
Biological Sciences Department

Office: 153 Long Hall
Phone:
Email: wenc@clemson.edu
Vita: Download CV

 

 Educational Background

Ph.D
Ohio University 1991

MS
Ohio University 1987

DDS
Shanghai JiaoTong University 1985

 Courses Taught

BIOL 1030 General Biology
BIOL/MICR 4930 Senior Seminar
MICR 4170/4170H Cancer and Aging
MICR 6170 Cancer and Aging

 Research Interests

Growth hormone (GH) receptor antagonists in clinical application. The role of prolactin (PRL) in breast cancer etiology. Developing PRL receptor antagonists in clinical application.

The following is the list of patents received related to GH and PRL research:

PATENTS (GRANTED):
1. "Growth Hormone Antagonist" John J. Kopchick and Wen Y. Chen, issued, Sep.27, 1994, Patent #5,350,836 (as Somervert, (http://www.somavert.com), a prescription medicine for acromegaly.
2. "Growth Hormone Antagonist" John J. Kopchick and Wen Y. Chen, issued, Oct.28, 1997, Patent #5,681,809
3. "Growth hormone receptor antagonists and methods of reducing growth hormone activity in mammal" John J. Kopchick and Wen Y. Chen, issued, Sept. 28, 1999, Patent #5,958,879
4. “Methods for treating acromegaly and giantism with growth hormone antagonists” John J. Kopchick and Wen Y. Chen, issued, June 24, 2003, Patent #6,583,115B1.
5. “DNA encoding growth hormone antagonist” John J. Kopchick and Wen Y. Chen, issued, Sept. 7, 2004, Patent #6,787,336 B1.
6. "Use of Anti-Prolactin Agents to Treat Proliferative Conditions" Wen Y. Chen and Thomas E. Wagner, issued, Oct 3, 2006. Patent #7,115,556.
7. "Bi-functional cancer treatment agents" Wen Y Chen and Thomas E. Wagner, issued, April 10, 2007. Patent #7,201,905.
8. “Human prolactin antagonist-angiogenesis inhibitor fusion proteins”. Wen Y Chen, March 4, 2008. Patent #7,339,027 B2
9. Compositions and methods for visualizing and eliminating cancer stem cells. Wen Y. Chen. Issued 2/11/2014 (#864846)
10. Methods for treating breast cancer with prolactin receptor agonist. Wen Y. Chen. Issued 6/21/2016, Patent #9370554

 Publications

(since 2008)
53. Yang N, Langenheim JF, Wang XD, Jiang J, Chen WY, and Frank SJ Activation of Growth Hormone Receptors by Growth Hormone and Growth Hormone Antagonist Dimers: Insights into Receptor Triggering. Mol Endocrinol. 22(4):978-88, 2008.
54. Jacquemart IC and WY Chen Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice. Int J Oncol. 34(2):517-28, 2009.
55. Seth Tomblyn, Alison E. B. Springs, John F. Langenheim, and Wen Y. Chen Combination therapy using three novel prolactin receptor antagonist based fusion proteins effectively inhibits tumor recurrence in HER2/neu mice. Int J Oncol. 34(4):1139-46, 2009.
56. Langenheim JF and Che WY Development of a Novel Ligand that Activates JAK2/STAT5 Signaling Through the Heterodimer of a Prolactin Receptor and Growth Hormone Receptor. J Recept Signal Transduct Res. 29(2):107-12, 2009.
57. Langenheim JF and Chen WY. Improving the pharmacokinetics of prolactin and growth hormone receptor agonists and antagonists by fusion to a synthetic albumin binding peptide. J Endocrinology. J Endocrinol. 203(3):375-87, 2009.
58. Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.Mol Endocrinol. 2011 Apr; 25(4):597-610.
59. Cong X, Langenheim JF and Chen WY Stromal-epithelial interactions modulate cross-talk between prolactin receptor and ErbB2/Neu in breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):157-69. Epub 2012 Jan 22
60. Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ. The role of prolactin receptor in GH signaling in breast cancer cells. Mol Endocrinol. 2013 Feb;27(2):266-79.
61. Yunfei Wen, Behrouz Zand, Miroslaw Szczepansk, Erkan Yuca, Amy Carroll, Rajesh Rajesh, Neslihan Alpay, Chandra Bartholomeusz, Yu Kang, Heather Dalton, Chad Pecot, Anadulce Hernandez-Herrera, Anna Loskin, Susan Lutgendorf, Bulent Ozpolat, Wen Chen, Gabriel Lopez-Berestein, Marta Szajnik, Preethi Gunaratne, Naoto Ueno, Robert Coleman, and Anil Sood Blockade of Tumoral Prolactin Promotes Autophagic Cell Death, Cell Rep. 2014 Apr 24;7(2):488-500.
62. De Lorenzo MS, Chen W, Baljinnyam E, Carlini MJ, La Perle K, Bishop SP, Wagner TE, Rabson AB, Vatner DE, Puricelli LI, Vatner SF. Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption. Aging Cell. 2014 Feb;13(1):102-10.
63. Chen WY The many faces of prolactin in breast cancer. Adv Exp Med Biol. 2015; 846:61-81. doi: 10.1007/978-3-319-12114-7_3.
64. Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers. Mol Endocrinol. 2016 May;30(5):504-17. doi: 10.1210/me.2015-1319. Epub 2016 Mar 22.
65. Eric Lee and Wen Y Chen. Prolactin and cisplatin combination treatment inhibit tumorspheres formation and tumor growth in mice. in press.